EVP Research, Development
Fady I. Malik, M.D., Ph.D. is the Executive Vice President of Research & Development at Cytokinetics, Incorporated (NASDAQ: CYTK), a position he has held since 2014.[[1]](https://cytokinetics.com/company/senior-management/team-member/fady-i-malik/)[[3]](https://insiderflow.io/insider/malik-fady-ibraham) He joined the company at its inception in 1998, contributing to its launch and leading discovery and development efforts that established Cytokinetics' portfolio of programs targeting muscle contractility for cardiovascular and neuromuscular diseases.[[1]](https://cytokinetics.com/company/senior-management/team-member/fady-i-malik/)
An internationally recognized cardiovascular physician-scientist, Malik holds over 20 patents and has authored or co-authored more than 60 publications in journals including *Science*, *Nature Medicine*, *The Lancet*, and the *New England Journal of Medicine*.[[1]](https://cytokinetics.com/company/senior-management/team-member/fady-i-malik/) He serves as Clinical Professor of Medicine in the Cardiology Division at the University of California, San Francisco, and previously was an Attending Interventional Cardiologist at the San Francisco Veterans Administration and UCSF Medical Centers.[[1]](https://cytokinetics.com/company/senior-management/team-member/fady-i-malik/) Malik also sits on the Board of Directors for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).[[1]](https://cytokinetics.com/company/senior-management/team-member/fady-i-malik/) He earned a B.S. in bioengineering from the University of California, Berkeley, and an M.D./Ph.D. from the University of California, San Francisco, where he completed his internal medicine residency and cardiology fellowship.[[1]](https://cytokinetics.com/company/senior-management/team-member/fady-i-malik/) Recently, as a corporate insider, he conducted share transactions, including selling 4,500 shares on April 7, 2026, under a Rule 10b5-1 plan, maintaining holdings of 153,902 shares.[[2]](https://www.sahmcapital.com/news/content/cytokinetics-evp-rd-malik-fady-ibraham-disposes-4500-shares-worth-293985-2026-04-08)[[5]](https://www.marketbeat.com/instant-alerts/cytokinetics-nasdaqcytk-evp-fady-ibraham-malik-sells-4500-shares-2026-04-08/)[[7]](https://www.stocktitan.net/sec-filings/CYTK/form-4-cytokinetics-inc-insider-trading-activity-e4cadd66d6cd.html)
View full insider profile →
